In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.

Adrianne L Jenner Tyler CassidyKatia BelaidMarie-Claude Bourgeois-DaigneaultMorgan Craig

Published in: Journal for immunotherapy of cancer (2021)

Based on our results, improved therapeutic schedules for combinations with enhancer OVs can be studied and implemented. Our results further underline the impact of interdisciplinary approaches to preclinical planning and the importance of computational approaches to drug discovery and development.

Keyphrases

drug discovery
molecular docking
transcription factor
binding protein
stem cells
mesenchymal stem cells
bone marrow